Physician profile
Robert M Ritchey
NPI 1942284286
$751.80
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $477 · 2020: $93.36 · 2021: $181.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $238.37 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $73.90 | 2019 | |
| Lilly USA, LLC | $64.93 | 2019-2020 | |
| Novo Nordisk INC | $61.45 | 2020-2021 | |
| Bioventus LLC | $56.88 | 2019 | |
| Nestle Healthcare Nutrition INC. | $46.22 | 2020-2021 | |
| Antares Pharma, INC. | $36.78 | 2021 | |
| Pfizer INC. | $35.06 | 2020-2021 | |
| Ucb, INC. | $29.95 | 2019 | |
| Horizon Therapeutics Plc | $26.61 | 2019 | |
| Glaxosmithkline, LLC. | $18.99 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $18.53 | 2021 | |
| Abbvie INC. | $17.63 | 2021 | |
| Amarin Pharma, INC. | $14.97 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.53 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ritchey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.